RESEARCHER PROFILE
Georgina Hughes,
Pharmacist & PhD Candidate
University of South Australia Clinical and Health Sciences
Registry of Senior Australians (ROSA)
South Australian Health and Medical Research Institute
Georgina Hughes is a pharmacist & PhD Candidate with the University of South Australia Clinical and Health Sciences and the Registry of Senior Australians (ROSA), undertaking research at South Australian Health and Medical Research Institute (SAHMRI).
Georgina’s PhD study and first published paper was on how to improve the safe and effective use of antidepressant medicines and optimise quality use of medicines in older people accessing residential aged care.
The study, published in the Journal of American Medical Directors Association (JAMDA), was led by Georgina, in collaboration with Professor Maria Inacio and Associate Professor Janet Sluggett. It’s Australia’s first national study investigating the use of antidepressants among older people living in residential aged care homes across the country, analysing the de-identified data of 779,659 residents from 3,371 aged care homes, between 2006 and 2019.
“We found antidepressants were used by 46.1% of residents in 2006 and this increased to 58.5% of residents in 2019,” Ms Hughes said.
“Nearly six in every ten residents of aged care homes are using an antidepressant, which is much higher than use in the general older population.”
The use of antidepressant medicines among older people in aged care homes in Australia is high, and there is a need for better mental health support and safer use of antidepressants to improve clinical care and health outcomes for older people.
Antidepressant medicines can have side effects, especially in older people, and Australia is one of the largest consumers globally.
Almost 60% of aged care home residents are using antidepressant medicines, prompting the need to investigate the reasons for such high usage.
Georgina talks to how big data is crucial in understanding and improving the use of antidepressant medicines in aged care, leading to better clinical care and health outcomes for older people in Australia.
Georgina is passionate about practice-informing, translational and innovative research to improve quality use of medicines and health outcomes.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Understanding the experience of pain for novel brain-based treatments
Associate Professor Tasha Stanton leads the Persistent Pain Research Group at SAHMRI. She is also co-Director of IIMPACT in Health at the University of South Australia, Adelaide. She is a clinical pain neuroscientist, with original training as a physiotherapist, and her research focusses on pain – why do we have it and why doesn’t it go away?
-
Radiation therapy techniques and combination treatments for sarcoma
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
As a radiation oncologist located in Sydney, Australia, Professor Hong is focused on treating patients with bone and soft tissue sarcoma. And as a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
